Ulipristal acetate finished product was authorised (as Esmya and Ulipristal Acetate Gedeon Richter) for treating moderate to severe symptoms of uterine fibroids (non-cancerous tumours of the womb) in women who had not reached the menopause. It was used either for up to 3 months before surgery to remove the fibroids or over the long-term but with treatment breaks in women who could not have surgery.
Ulipristal acetate pharmacodynamics
Ulipristal acetate is a selective progesterone receptor modulator and has antagonistic and partial agonistic effects on progesterone receptors. It binds to the progesterone receptor in the human body to prevent the combination of progesterone and progesterone receptor. The efficacy of ulipristal acetate depends on the time of administration in the menstrual cycle. Administration in the mid-stage of follicular hyperplasia will inhibit follicle formation and reduce the concentration of estradiol. Administration of luteinizing hormone during the peak period can delay the rupture of follicles for 5-9 days. Early administration of the corpus luteum can not significantly delay the maturation of the endometrium, but it can reduce the thickness of the endometrium by 0.6±2.2mm (mean±SD).
Ulipristal acetate side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Ulipristal Acetate Tablet was studied in an open-label multicenter trial (Open-Label Study) and in a comparative, randomized, single-blind, multicenter trial (Single-Blind Comparative Study). In these studies, a total of 2,637 (1,533 + 1,104) women in the 30 mg ulipristal acetate groups were included in the safety analysis. The mean age of women who received ulipristal acetate was 24.5 years and the mean body mass index (BMI) was 25.3. The racial demographics of those enrolled were 67% Caucasian, 20% Black or African American, 2% Asian, and 12% other.
The most common adverse reactions (≥ 10%) in the clinical trials for women receiving ella were headache (18% overall) and nausea (12% overall) and abdominal and upper abdominal pain (12% overall). Table 1 lists those adverse reactions that were reported in ≥ 5% of subjects in the clinical studies.
How to use ulipristal acetate rationally?
Drugs must be used rationally to avoid abuse. Prescription drugs should be prescribed by a doctor, and over-the-counter drugs should be read carefully.
Ulipristal acetate is a prescription drug and must be prescribed by a doctor according to your condition. Self-administration may increase your risk of unreasonable use of drugs: waste of drug resources, delayed disease, drug resistance, and serious adverse drug reactions.
Ulipristal acetate needs to be used in full and full course of treatment following the doctor’s prescription. Your symptoms may be relieved before the condition is fully controlled, but do not reduce the dose or stop the medication easily.
Where to buy ulipristal acetate for medicine production?
Maxmedchem, a global supplier of Ulipristal acetate, 126784-99-4 offers for your requirements of RND / Development quantities or commercials, based on status of the product. We can also offer its intermediates with supportive technical package required for evaluation.
a) Free sample can be supplied.
b) Guide our clients by professional knowledge and teach them how to use our product after sales.
c) Accept SGS,BV any other third-party inspection before loading.
d) High quality best price Guaranteed.
MSDS: MSDS available.
COA: COA can be available if you send us inquiry.
Email us at: email@example.com for more details.